[ad_1]
KUALA LUMPUR: The selection of the Covid-19 vaccine produced by the international pharmaceutical company Pfizer is based on an interim report from clinical trials of its level of effectiveness, which is 95 percent, Dewan Rakyat was told today.
Science, Technology and Innovation Minister Khairy Jamaluddin said the report was published in The New England Journal of Medicine on December 10, and even the government had access to the data to evaluate the quality, safety and effectiveness of the vaccine. .
“The vaccine has also received Emergency Use Authorization from seven countries, including the United Kingdom, the United States, Bahrain, Canada, Saudi Arabia, Mexico and Singapore.
“However, the final decision for the purchase, as well as the use, of the vaccine in Malaysia is subject to registration and approval by the National Division of Pharmaceutical Regulation (NPRA) of the Ministry of Health,” he said during the question time of the Minister. .
Apart from that, he said that the Special Committee on Access to the Supply of Covid-19 Vaccines, which was established earlier, was also considering other vaccines that are in phase three of clinical trials with the purpose of herd immunity of up to 70 percent of the country’s total. population.
An announcement on the matter and a list of priority vaccine recipients will be made soon, he added.
Khairy said this in response to a question from Lim Guan Eng (PH-Bagan) about the cost, effectiveness, vaccine coverage and side effects of the vaccine, as well as the rationale for the selection of the vaccine by Pfizer.Called
[ad_2]
